Bioqube Ventures
Bioqube Ventures NV is a venture capital firm based in Brussels, Belgium, established in 2016. The company specializes in early-stage investments in the life sciences sector, particularly targeting European biotech companies that are developing innovative therapeutic assets and technologies. Bioqube Ventures focuses on investments in the Benelux countries, France, and Germany, aiming to advance scientific innovation and support companies with medicines in the testing phase. The firm employs a dual investment model that includes traditional early investment rounds and special attention to projects that require additional de-risking before launching new ventures. With a diverse team of fund managers, sector experts, and serial entrepreneurs, Bioqube Ventures takes a hands-on approach to drive growth and maximize value for its portfolio companies and investors.
Anavo Therapeutics is the first company to systematically drug phosphatases, a rich target space previously considered undruggable for decades. We have attracted world-leading scientific expertise in phosphatase-driven disease biology and drug discovery to unlock the full potential of phosphatase-targeted allosteric modulators. In oncology, Anavo is developing multiple first-in-class therapeutic programs and will build on partnerships around its platform to establish a rich pipeline across several indications
Egle Therapeutics is an emerging biotechnology company focused on developing First-In-Class immunotherapies targeting immune suppressor regulatory T-cells (Tregs) for oncology and autoimmune diseases. The company was founded in 2020 and is based in Paris, France.
Anavo Therapeutics is the first company to systematically drug phosphatases, a rich target space previously considered undruggable for decades. We have attracted world-leading scientific expertise in phosphatase-driven disease biology and drug discovery to unlock the full potential of phosphatase-targeted allosteric modulators. In oncology, Anavo is developing multiple first-in-class therapeutic programs and will build on partnerships around its platform to establish a rich pipeline across several indications
Primmune Therapeutics is developing small molecule, orally-administered toll-like receptor 7 (TLR7) agonists to attack tumors and potentiate adaptive cancer immunotherapies, such as checkpoint inhibitors, to improve overall response rates and treatment durability.
Enhanc3D Genomics is a functional genomics firm that studies the three-dimensional organization of DNA in health and disease. The company's GenLink3D platform helps comprehend the impact of such mutations on distant genes, thereby revealing how they influence disease progression.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.